The stock of EXACT Sciences Corporation (NASDAQ:EXAS) is a huge mover today! About 5.05 million shares traded hands or 102.81% up from the average. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 133.38% since April 14, 2016 and is uptrending. It has outperformed by 128.69% the S&P500.
The move comes after 5 months negative chart setup for the $1.64 billion company. It was reported on Nov, 16 by Barchart.com. We have $14.35 PT which if reached, will make NASDAQ:EXAS worth $98.40 million less.
EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage
Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. EXACT Sciences has been the topic of 27 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Neutral” rating given on Tuesday, October 6 by Goldman Sachs. Roth Capital maintained it with “Buy” rating and $12 target price in Friday, October 30 report. The firm has “Buy” rating by TH Capital given on Friday, October 30. The rating was maintained by TH Capital with “Buy” on Tuesday, October 6. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Hold” rating by Benchmark on Tuesday, October 6. The stock has “Buy” rating given by Mizuho on Wednesday, October 7. As per Friday, December 18, the company rating was initiated by BTIG Research. The company was maintained on Tuesday, November 24 by Lake Street. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Hold” rating by Benchmark on Wednesday, October 26. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Craig Hallum on Thursday, October 1.
According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”
Insitutional Activity: The institutional sentiment increased to 1.42 in Q2 2016. Its up 0.70, from 0.72 in 2016Q1. The ratio increased, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.
Adage Prtnrs Grp Incorporated Limited Company holds 0.01% or 300,000 shares in its portfolio. Strs Ohio has 0.04% invested in the company for 650,000 shares. Barclays Public Limited Co last reported 47,087 shares in the company. Orbimed Ltd Co holds 0.27% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS) for 2.13M shares. The Wisconsin-based Broadview Advsr Ltd Llc has invested 1.05% in EXACT Sciences Corporation (NASDAQ:EXAS). Leisure Mngmt accumulated 18,786 shares or 0.26% of the stock. Focused Wealth Mgmt Inc reported 175 shares or 0% of all its holdings. Blackrock Japan Limited has 0% invested in the company for 97,661 shares. Moreover, Voya Inv Mgmt Ltd Liability Company has 0% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 41,805 shares. Rhumbline Advisers has 0% invested in the company for 106,088 shares. Manufacturers Life Ins Co The last reported 66,555 shares in the company. Point72 Asset Mgmt L P has invested 0.04% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Principal Fincl Gp has 251,439 shares for 0% of their US portfolio. The New York-based Product Partners Ltd Liability has invested 0.22% in EXACT Sciences Corporation (NASDAQ:EXAS). Metropolitan Life Insur New York has 68,335 shares for 0.01% of their US portfolio.
Insider Transactions: Since July 25, 2016, the stock had 2 insider purchases, and 6 insider sales for $25.84 million net activity. COWARD D SCOTT sold 1,701 shares worth $30,584. Another trade for 7,359 shares valued at $109,060 was sold by ARORA MANEESH. Shares for $60,613 were bought by Zanotti Katherine S. Another trade for 600,000 shares valued at $10.48M was sold by Conroy Kevin T. LIDGARD GRAHAM PETER also sold $109,416 worth of EXACT Sciences Corporation (NASDAQ:EXAS) shares. 5,000 shares with value of $90,500 were bought by Sterling Lionel on Thursday, September 1.
More important recent EXACT Sciences Corporation (NASDAQ:EXAS) news were published by: Fool.com which released: “1 Sentence in Exact Sciences Corporation’s Q3 Report Cost It 16% in October” on November 07, 2016, also Fool.com published article titled: “Here’s Why Exact Sciences Corporation’s Stock Is Dropping Today”, Fool.com published: “Exact Sciences Corp. Gets a Better Balance Sheet” on November 03, 2016. More interesting news about EXACT Sciences Corporation (NASDAQ:EXAS) was released by: Streetinsider.com and their article: “Form 4 EXACT SCIENCES CORP For: Nov 11 Filed by: Conroy Kevin T” with publication date: November 16, 2016.
EXAS Company Profile
Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.